Ubs Group Ag Aldeyra Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 48,316 shares of ALDX stock, worth $186,499. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,316

Previous 53,077 8.97%

Holding current value

$186,499

Previous $186,000 15.59%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.77 - $4.22 $13,187 - $20,091	-4,761 Reduced 8.97%	48,316 $157,000
Q4 2023 Feb 09, 2024	SELL	$1.47 - $6.06 $31,631 - $130,399	-21,518 Reduced 28.85%	53,077 $186,000
Q3 2023 Nov 09, 2023	SELL	$6.11 - $8.16 $89,413 - $119,413	-14,634 Reduced 16.4%	74,595 $498,000
Q2 2023 Aug 11, 2023	BUY	$7.11 - $11.89 $588,857 - $984,741	82,821 Added 1292.46%	89,229 $748,000
Q1 2023 May 12, 2023	BUY	$5.77 - $9.93 $26,588 - $45,757	4,608 Added 256.0%	6,408 $63,000

Q4 2022 Feb 08, 2023	SELL	$5.08 - $7.09 $121,935 - $170,181	-24,003 Reduced 93.02%	1,800 $12,000
Q3 2022 Nov 10, 2022	SELL	$3.8 - $7.74 $2.79 Million - $5.69 Million	-734,694 Reduced 96.61%	25,803 $138,000
Q2 2022 Aug 10, 2022	SELL	$2.43 - $4.85 $485,747 - $969,495	-199,896 Reduced 20.81%	760,497 $3.04 Million
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $2.52 Million - $4.01 Million	776,593 Added 422.52%	960,393 $4.27 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $163,159 - $448,921	46,617 Added 33.98%	183,800 $735,000
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $971,117 - $1.38 Million	122,307 Added 822.18%	137,183 $1.21 Million
Q2 2021 Aug 13, 2021	SELL	$10.44 - $14.85 $355,283 - $505,360	-34,031 Reduced 69.58%	14,876 $168,000
Q1 2021 May 12, 2021	SELL	$6.53 - $14.42 $349,178 - $771,080	-53,473 Reduced 52.23%	48,907 $581,000
Q4 2020 Feb 11, 2021	SELL	$6.31 - $8.13 $23,100 - $29,763	-3,661 Reduced 3.45%	102,380 $702,000
Q3 2020 Nov 12, 2020	BUY	$4.0 - $7.53 $411,292 - $774,257	102,823 Added 3195.25%	106,041 $785,000
Q2 2020 Jul 31, 2020	SELL	$1.97 - $5.05 $23,513 - $60,276	-11,936 Reduced 78.76%	3,218 $14,000
Q1 2020 May 01, 2020	SELL	$1.62 - $6.4 $42,957 - $169,708	-26,517 Reduced 63.63%	15,154 $37,000
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $78,423 - $132,308	16,580 Added 66.08%	41,671 $242,000
Q3 2019 Nov 14, 2019	BUY	$4.41 - $6.12 $69,744 - $96,787	15,815 Added 170.49%	25,091 $132,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $21,486 - $32,229	-3,581 Reduced 27.85%	9,276 $56,000
Q1 2019 May 14, 2019	BUY	$7.14 - $9.85 $999 - $1,379	140 Added 1.1%	12,857 $116,000
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $10,541 - $19,297	1,452 Added 12.89%	12,717 $106,000
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $27,941 - $58,964	4,109 Added 57.42%	11,265 $155,000
Q2 2018 Aug 14, 2018	BUY	$6.95 - $9.18 $4,969 - $6,563	715 Added 11.1%	7,156 $57,000
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $29,579 - $40,192	4,516 Added 234.6%	6,441 $48,000
Q4 2017 Feb 14, 2018	BUY	$5.7 - $7.75 $3,767 - $5,122	661 Added 52.29%	1,925 $13,000
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $608 - $1,684	156 Added 14.08%	1,264 $9,000
Q2 2017 Aug 14, 2017	SELL	N/A	-721 Reduced 39.42%	1,108 $5,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,829	1,829 $9,000

Others Institutions Holding ALDX

# of Institutions

106

Shares Held

35.4M

Call Options Held

104K

Put Options Held

88.1K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $225M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account